Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, ...

(RTTNews) - Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. The study focuses on: development and optimization ...

With May the Fourth waiting in the (Starfighter) wings, do keep your eyes peeled for all the new Star Wars releases at Disney Store — after all, to quote our favorite green Jedi Grand Master, when it ...

The China National Intellectual Property Administration approved the patent covering Hoth’s HT-KIT technology, which is designed to induce apoptosis (programmed cell death) in cancer cells by ...

Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European ...

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism. Processing and qualitative evaluation of tissue samples by a board-certified ...

Shares of Hoth Therapeutics Inc (NASDAQ:HOTH) advanced 3.6% in premarket trading on Wednesday after the clinical-stage ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at ...

Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and ...